Search Results

You are looking at 11 - 20 of 135 items for :

Clear All
Full access

Ellin Berman

Among the challenges of treating women with chronic myeloid leukemia (CML) who may want to become pregnant is the lack of clear information regarding the dose of tyrosine kinase inhibitors (TKIs) and the exposure time. “The concept of stopping

Full access

-Myers Squibb Background: GLEEVEC (imatinib; Novartis Pharmaceuticals Corporation, East Hanover, NJ) was the first tyrosine kinase inhibitor (TKI) approved for use in the United States and remains the most commonly prescribed BCR-ABL TKI, followed by SPRYCEL

Full access

Eric Jonasch and Robert J. Motzer

carcinoma; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor. Although individual studies have, for the most part, not shown a significant intra-study increase in overall survival (OS) for patients treated with antiangiogenic

Full access

Henry J. Henk, Lena E. Winestone, Jennifer J. Wilkes, Laura Becker, Pamela Morin, Gary H. Lyman and Eric J. Chow

Background: Chronic myeloid leukemia (CML) treatment improved considerably after introduction of oral tyrosine kinase inhibitors (TKI). As a result, the number of patients living with CML may reach 250,000 by 2040. We track changes in TKI treatment

Full access

Aaron T. Gerds, Jason Gotlib, Prithviraj Bose, Michael W. Deininger, Andrew Dunbar, Amro Elshoury, Tracy I. George, Ivana Gojo, Krishna Gundabolu, Elizabeth Hexner, Gabriela Hobbs, Tania Jain, Catriona Jamieson, Andrew T. Kuykendall, Brandon McMahon, Sanjay R. Mohan, Vivian Oehler, Stephen Oh, Animesh Pardanani, Nikolai Podoltsev, Erik Ranheim, Lindsay Rein, Rachel Salit, David S. Snyder, Brady L. Stein, Moshe Talpaz, Swapna Thota, Pankit Vachhani, Martha Wadleigh, Katherine Walsh, Dawn C. Ward, Mary Anne Bergman and Hema Sundar

another WHO-defined myeloid neoplasm. 11 The identification of specific TK fusion genes and the emergence of TK inhibitors (TKIs) has significantly improved the diagnosis and treatment of some patients with MLN-Eo. 12 The management of patients with MLN

Full access

Rogerio A. Lilenbaum and Leora A. Horn

gefitinib. “If the EGFR mutation is not present, do not treat the patient with a tyrosine kinase inhibitor [TKI]. If you need to treat the patient before receiving the genomic profiling report, use chemotherapy first. You can always switch to gefitinib (or

Full access

Helena A. Yu and Gregory J. Riely

. First-Generation EGFR Tyrosine Kinase Inhibitors Gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors (TKIs) that were approved for the treatment of patients with non–small cell lung cancer (NSCLC). These drugs inhibit kinase activity

Full access

Leora Horn

progression-free survival in the EGFR mutation-positive subgroup were not apparent for overall survival. 6 Since the IPASS trial, many trials have compared EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy in the first-line treatment of patients

Full access

Presenter : Eunice S. Wang

chemoresistance, Dr. Wang noted. Numerous oral tyrosine kinase inhibitors against FLT3 (also known as FLT3-TKIs) are in development. The first-generation FLT3-TKIs (lestaurtinib, midostaurin, sorafenib) are multikinase targeted agents that were repurposed as

Full access

Hema Sundar and Jerald Radich

injections and it was discovered that she was no longer adhering to the TKI regimen as a reaction to her poorly controlled hyperglycemia. Nilotinib was therefore discontinued, and she was started on dasatinib 100 mg daily. The patient was asked to stop